4D pharma will present preclinical data on its asthma programme at the Keystone Symposium: Microbiome in Health and Disease meeting from February 5 - 9 in Keystone, Colorado. The company will present a poster on its lead candidate, MRx0004, a single-strain live biotherapeutic under investigation for the treatment of asthma which is set to hit the clinic in 2018.

The data presented are:

Immunomodulatory effects of a commensal gut microbe alleviate inflammatory responses in an animal model of severe asthma through reduction of neutrophil infiltration in the lung, presented by Phillip Cowie, PhD, 4D Pharma Research.

Download PDF